Please Verify Your Age

Description

Product Overview

Retatrutide (LY3437943) is an investigational synthetic peptide and one of the most closely watched compounds in modern metabolic research. It is a single-chain, fatty-acid-acylated “triple agonist” engineered to activate three receptors at once — the GIP, GLP-1 and glucagon receptors — pairing the incretin effects of dual agonists with the added energy-expenditure signaling attributed to glucagon. Researchers study it as a next-generation successor to earlier GLP-1 and GIP/GLP-1 tool compounds.

Research Information

In preclinical and in-vitro models, retatrutide is investigated for how simultaneous tri-receptor activation influences appetite regulation, glucose-dependent insulin secretion, insulin sensitivity, lipid handling and hepatic fat content. The glucagon component is of particular interest because it is associated with increased energy expenditure, allowing researchers to compare metabolic and body-weight outcomes against GLP-in 1-only and GIP/GLP-1 agonists. Studies also examine dose-response relationships and how balancing the three receptor activities shapes overall efficacy. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption.